Matches in Wikidata for { <http://www.wikidata.org/entity/Q80612990> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- Q80612990 description "article scientifique (publié 2008)" @default.
- Q80612990 description "artikull shkencor i botuar më 01 janar 2008" @default.
- Q80612990 description "artículu científicu espublizáu en xineru de 2008" @default.
- Q80612990 description "im Jahr 2008 veröffentlichter wissenschaftlicher Artikel" @default.
- Q80612990 description "scientific article published on 01 January 2008" @default.
- Q80612990 description "wetenschappelijk artikel" @default.
- Q80612990 description "наукова стаття, опублікована в січні 2008" @default.
- Q80612990 name "Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality" @default.
- Q80612990 name "Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality" @default.
- Q80612990 name "Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality" @default.
- Q80612990 type Item @default.
- Q80612990 label "Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality" @default.
- Q80612990 label "Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality" @default.
- Q80612990 label "Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality" @default.
- Q80612990 prefLabel "Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality" @default.
- Q80612990 prefLabel "Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality" @default.
- Q80612990 prefLabel "Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality" @default.
- Q80612990 P1433 Q80612990-4F44B16B-9F63-41D0-B34B-9F32DD8E9C94 @default.
- Q80612990 P1476 Q80612990-78E7EA0F-4254-4674-9303-4C5ACDD36F6B @default.
- Q80612990 P2093 Q80612990-52A84852-6AB5-4C5E-B564-847BCB9014E0 @default.
- Q80612990 P2093 Q80612990-8D3DC7B7-79F8-4001-AA7D-F964A76DC553 @default.
- Q80612990 P2093 Q80612990-8E34E91A-4316-4D46-8189-14599B7DBBC1 @default.
- Q80612990 P2093 Q80612990-92CA3E48-1F70-4DE8-A1F9-66821BC75C14 @default.
- Q80612990 P2093 Q80612990-9823FBB8-64BD-4BB1-8727-F0AACC864493 @default.
- Q80612990 P2093 Q80612990-E99483F0-D64D-4F78-BA27-1038603F8991 @default.
- Q80612990 P2860 Q80612990-09905728-A2E8-4E77-A76D-CDA9FCC1BF84 @default.
- Q80612990 P2860 Q80612990-2B7B9389-CEAC-4C9A-8E8F-B10AB1D117BB @default.
- Q80612990 P2860 Q80612990-3A20B4F4-337F-428C-A509-51B060692157 @default.
- Q80612990 P2860 Q80612990-3ED38520-AAAE-4B38-910F-F1E2D340FE6B @default.
- Q80612990 P2860 Q80612990-48255652-7C79-435A-AA71-61DF2570C3A6 @default.
- Q80612990 P2860 Q80612990-4A0B005F-C459-4C89-9CDA-75878B4FC0D5 @default.
- Q80612990 P2860 Q80612990-78541DA8-7089-4BC9-AE93-BA0AE53F7E27 @default.
- Q80612990 P2860 Q80612990-845ED70A-1620-4AED-8DB4-8C7B427F0642 @default.
- Q80612990 P2860 Q80612990-B5C34596-A747-4C6E-ADEA-C257FC64531E @default.
- Q80612990 P2860 Q80612990-E41BD864-E66F-4936-B09C-96C0377A94EF @default.
- Q80612990 P304 Q80612990-BFAB7BB8-F818-4DB4-B653-D7089680341B @default.
- Q80612990 P31 Q80612990-56312CF6-D3D9-4795-B913-FC01ED1D1776 @default.
- Q80612990 P356 Q80612990-C1D079A8-5AF7-42CE-903F-83AC3140ABFC @default.
- Q80612990 P407 Q80612990-C3C98774-C1D4-44FB-9652-0FB287884FC3 @default.
- Q80612990 P433 Q80612990-844EB1E1-5423-423C-A88C-F972F02F561C @default.
- Q80612990 P478 Q80612990-993D04DF-0EFC-4DE3-ABC5-0262EE78B6A2 @default.
- Q80612990 P577 Q80612990-158EA943-8B63-4916-B314-BAD47BA9D627 @default.
- Q80612990 P698 Q80612990-2DD538B8-04DF-44B3-B948-AB0A2DE458FF @default.
- Q80612990 P921 Q80612990-B8ECC4B8-2AB0-4523-B839-6F10349B6F65 @default.
- Q80612990 P356 J.UROLOGY.2007.08.028 @default.
- Q80612990 P698 18242382 @default.
- Q80612990 P1433 Q7900884 @default.
- Q80612990 P1476 "Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality" @default.
- Q80612990 P2093 "Anthony V D'Amico" @default.
- Q80612990 P2093 "Christine S Chung" @default.
- Q80612990 P2093 "David McLeod" @default.
- Q80612990 P2093 "Jennifer Cullen" @default.
- Q80612990 P2093 "Ming-Hui Chen" @default.
- Q80612990 P2093 "Peter Carroll" @default.
- Q80612990 P2860 Q25938997 @default.
- Q80612990 P2860 Q29616123 @default.
- Q80612990 P2860 Q29616218 @default.
- Q80612990 P2860 Q33611613 @default.
- Q80612990 P2860 Q39724803 @default.
- Q80612990 P2860 Q44019265 @default.
- Q80612990 P2860 Q47331119 @default.
- Q80612990 P2860 Q52957665 @default.
- Q80612990 P2860 Q81231643 @default.
- Q80612990 P2860 Q81280205 @default.
- Q80612990 P304 "136-140" @default.
- Q80612990 P31 Q13442814 @default.
- Q80612990 P356 "10.1016/J.UROLOGY.2007.08.028" @default.
- Q80612990 P407 Q1860 @default.
- Q80612990 P433 "1" @default.
- Q80612990 P478 "71" @default.
- Q80612990 P577 "2008-01-01T00:00:00Z" @default.
- Q80612990 P698 "18242382" @default.
- Q80612990 P921 Q181257 @default.